October 10, 2015 – Creative Medical Health, Inc. (CMH) announces selection of PRC Clinical, a contract research organization (CRO) to oversee the CaverStem® Clinical Trial.
“CMH is pleased to announce that PRC Clinical has been awarded the contract to provide study monitoring and management services on our Caverstem™ clinical trial for the treatment of erectile dysfunction being conducted at UCLA Harbor Medical Center by LA Biomed.” stated Timothy Warbington, CEO of Creative Medical Health, Inc.
“It was an obvious choice to pick PRC Clinical. Their team is local, responsive, thorough and has an impressive track record in our space”, stated Don Dickerson, CMH’s Chief Operating Officer.
About PRC Clinical
PRC Clinical™ is a CRO in the San Francisco Bay Area committed to delivering world-class quality and client satisfaction by providing personalized clinical services to pharmaceutical and biotechnology companies. PRC Clinical project teams are highly skilled and experienced clinical professionals; Services include Project Management, Regional Monitoring, Data Management, Electronic Data Capture (EDC), Biostatistics/IRT, Central Laboratory Services and Global Clinical Payment Services. PRC Clinical has experience in conducting all phases of studies, including Registries and orphan/rare disease studies and in a wide range of disease, delivery and therapeutic areas. Please visit www.prcclinical.com
Creative Medical Health, Inc. owns U.S. patent #20,090,311,223, titled “Treatment of Erectile Dysfunction by Stem Cell Therapy,” which covers the use of various stem cells for treatment of patients who do not respond to Viagra, Cialis and Levitra. In contrast to pharmaceutical agents, the CaverStem® treatment developed by Creative Medical Health, Inc. involves regenerating the blood vessels and smooth muscle of the penis, thus offering the possibility of permanent regeneration, not a temporary remedy.
The medical procedure involves extracting stem cells from the patient’s own bone marrow, processing them and subsequent administration into the penis. A peer-reviewed study describing the first patient treated with this procedure may be found at http://www.translational-medicine.com/content/pdf/1479-5876-11-139.pdf.
“There are approximately 30 million patients with erectile dysfunction in the USA. Of these, 30% do not respond to pharmaceutical interventions, which represents approximately 9 million potential patients that could benefit from our approach,” stated Timothy Warbington, CEO of Creative Medical Health, Inc. “Given that this patient group has limited alternatives besides costly implants and injections before intercourse, which can be associated with horrific side effects, we believe it is our responsibility to accelerate development of this program in a timely manner.”
The use of bone marrow stem cells is currently part of medical practice in bone marrow transplantation, and is currently in advanced clinical trials for conditions including heart failure, peripheral artery disease and stroke. Creative Medical Health, Inc. is the first to patent and subsequently clinically validate the feasibility of applying this form of stem cell therapy to urological conditions.
About Creative Medical Health, Inc.:
CREATIVE MEDICAL HEALTH, INC., in collaboration with leading U.S. universities, physicians and scientists, has developed and tested our patented treatment of various medical conditions with stem cell technology. Our area of concentration is the scientific and evidence-based approach to the approximately $30 billion per year complementary and alternative medicine market in the United States and $250 billion worldwide market. For more information about Creative Medical Technologies go to www.creativemedicalhealth.com.
Creative Medical Health, Inc.
Tim Warbington, 602-680-7439